Osaka, Japan

Kazuo Sekiguchi

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Kitajima, JP (2011)
  • Otsu, JP (2011 - 2012)
  • Osaka, JP (2013 - 2014)

Company Filing History:


Years Active: 2011-2014

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Kazuo Sekiguchi: Innovator in Anticancer Compounds

Introduction

Kazuo Sekiguchi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anticancer compounds. With a total of 5 patents to his name, Sekiguchi's work is recognized for its innovative approach to cancer treatment.

Latest Patents

Among his latest patents, Sekiguchi has developed di-substituted pyridine derivatives that exhibit excellent antitumor effects. This novel compound is represented by a specific general formula, which includes various substituents that enhance its efficacy. Additionally, he has patented a heterocyclic compound and its pharmaceutical composition, further showcasing his expertise in medicinal chemistry.

Career Highlights

Kazuo Sekiguchi is affiliated with Otsuka Pharmaceutical Company, Limited, where he continues to push the boundaries of pharmaceutical innovation. His work has not only contributed to the scientific community but has also aimed to improve patient outcomes in cancer therapy.

Collaborations

Throughout his career, Sekiguchi has collaborated with notable colleagues, including Takumi Sumida and Hideki Takasu. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.

Conclusion

Kazuo Sekiguchi's contributions to the field of pharmaceuticals, particularly in anticancer research, highlight his role as a leading inventor. His innovative patents and collaborations reflect a commitment to advancing medical science and improving treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…